Press Releases

India’s Pharmaceuticals Market Will Skyrocket from $20 Billion in 2015 to $55 Billion by 2020

The pharmaceuticals market in India, valued at $20 billion in 2015, is set to soar to $55 billion by 2020, representing an impressive Compound Annual Growth Rate (CAGR) of 22.4%, says research and consulting firm GlobalData.

According to the company’s latest report*, India’s rapidly growing generics market is the primary driver of the nation’s pharmaceutical sector, with sales expected to soar by nearly 84% to $26.1 billion in 2016. Generic drugs, with their low costs and easy accessibility, now dominate India’s pharmaceutical space, accounting for around 70% of the market.

Adam Dion, MSc, GlobalData’s Senior Industry Analyst, states that: “India supplies 20% of global generic medicines in terms of export volume, making the country the largest provider of generic medicines globally.

“Indeed, Indian pharmaceutical companies are now exporting to countries like Brazil, Mexico, South Africa, Russia and Japan, and, according to India’s Ministry of Commerce and Industry, the nation’s pharmaceutical export segment has more than doubled from $7.8 billion in 2008 to $16.5 billion in 2014.”

Another driver of India’s pharmaceutical sector is the potentially lucrative biosimilars market, which is expected to increase to $40 billion globally by 2020, as biologic treatments are introduced for diseases such as diabetes, cancer, multiple sclerosis, and rheumatoid arthritis.

Dion explains: “One company benefiting from its leading position in the biosimilars market is Dr. Reddy’s. In 2007, Dr. Reddy’s was the first to launch a biosimilar version to Roche’s cancer drug rituximab (Rituxan), and has four other biosimilars on the market.

“The company’s drug characterization strategy and quality measures give Dr. Reddy’s a significant competitive advantage that reduces the uncertainty of potential outcome differences when used in patients.”

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

This report provides analysis of the pharmaceutical market in India, identifying key trends in the country’s healthcare space, and providing insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. It also discusses the trends and segmentation of India’s pharmaceutical and medical device sectors, with annualized market data from 2014 and forecast to 2020.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.View Report

………………………………………………………………………………………………………………………………………………………………………..

China’s Medical Device Market Will Burgeon Beyond $50 Billion by 2020

The Chinese medical device market is set to rise from $27.7 billion in 2014 to an estimated $50.8 billion by 2020, expanding at a strong Compound Annual Growth Rate (CAGR) of 10.6%, says research and consulting firm GlobalData.

According to the company’s latest report*, this substantial increase will be driven by a number of factors, including the increasing prevalence of metabolic syndromes and chronic diseases, an aging population, as well as government investment.

The leading device companies in China who will benefit are Siemens Healthcare, GE Healthcare, Philips Healthcare, Medtronic and Roche.

Dion comments: “The dominant player in terms of revenue in China is Siemens, which has a best-in-class portfolio of ultrasound and medical imaging solutions.

China’s diagnostics market will experience the biggest growth of all medical device segments, rising from $9.3 billion in 2014 to $20.1 billion by 2020, representing a CAGR of 13.8%.

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

This report provides analysis of the healthcare, regulatory, and reimbursement landscape in China, including an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.View Report

………………………………………………………………………………………………………………………………………………………………………..

Indonesia’s Pharmaceutical Market Will Continue Rapid Growth to $12.6 Billion by 2020

The pharmaceutical market in Indonesia more than doubled from just under $3 billion in 2008 to reach approximately $7 billion in 2015 and is anticipated to increase further to $12.6 billion by 2020, driven primarily by the Indonesian government’s economic and healthcare initiatives, according to research and consulting firm GlobalData.

The company’s latest report* states that Indonesia’s pharmaceutical sector will be boosted by the establishment of a universal healthcare scheme, known as the Jaminan Kesehatan Nasional. This was launched in January 2014 with the aim of providing health insurance to 250 million Indonesian citizens by 2019, which would make it the world’s largest social health insurance.

Adam Dion, MSc, GlobalData’s Senior Industry Analyst, says new economic policy packages, the high prevalence of infectious diseases, widespread generic drug supply, increasing affordability of healthcare products and the large over-the-counter medicines market will also help to drive growth in Indonesia’s pharmaceutical sector.

Despite the overall positive trend, there are a number of factors limiting the expansion of Indonesia’s healthcare industry, including the imposition of an Import Tax in 2010, a high level of counterfeit medicines, periodic price cuts to branded generics, and limited access to healthcare facilities for the rural population.

Indonesia’s pharmaceutical production plants are concentrated around Jakarta and Java, resulting in wide geographical discrepancies. In remote areas, many health centers and pharmacies are facing drug supply shortages due to insufficient production by manufacturers and a weak distribution system.

“Furthermore, the high cost of branded medicines combined with a lack of public reimbursement for expensive and novel drug therapies limits access to efficient medicines. However, this offers a significant opportunity to generic players.”

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Indonesia

This report provides information on Indonesia’s healthcare, regulatory, and reimbursement landscape, with annualized market data on the pharmaceutical and medical devices sectors from 2014 and forecast to 2020. It includes detailed analysis of the political and economic environment, covering economic indicators, demographics, and healthcare infrastructure and expenditure in Indonesia.View Report

………………………………………………………………………………………………………………………………………………………………………..

Changing Attitudes towards Over-the-Counter Drugs Encouraging New Competitors

Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to Over-the-Counter (OTC) non-prescription status is one of the main drivers of growth within the OTC drugs market, says business intelligence provider GBI Research.

According to the company’s latest CBR Pharma report*, demand for OTC drugs is rising as patients are taking a more proactive approach to treating ailments.

“Indeed, pharmacists can expect to attend to rarer and more complex conditions, and as such will be a key part of the movement towards greater patient autonomy and expanded access to healthcare.”

The report also states that the rising costs of healthcare will drive the OTC drugs market, as patients are encouraged to eschew prescription treatments for lower-priced alternatives.

Cost-conscious insurance programs will drive this trend even further by encouraging consumers to self-treat, especially with regard to chronic conditions, by providing dramatically increased incentives for the use of newly-approved OTC drugs.

“This cultural shift towards greater self-reliance in healthcare means new competitors have identified the potential of OTC products, with many pursuing major acquisitions to gain a foothold for growth. Even food companies such as Danone and Nestle are focusing on OTC products, as they look to capitalize on growing consumer interest in personal wellbeing,” Ladda concludes.

*The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects

This report provides analysis of the Over-the-Counter (OTC) drugs space, including information on current and future trends in the OTC market, consumer attitudes towards OTC drugs, and new distribution channels, technologies and education reshaping the arena.View Report

………………………………………………………………………………………………………………………………………………………………………..

Pharma Companies Must Assess Real-World Evidence to Keep Up with Shifts in the Global Market Access Landscape

As the overall costs of drugs continue to increase and pricing pressures shift the dynamics of the healthcare market, pharmaceutical companies must analyze real-world trends in different treatment spaces, and assess existing and expected levels of competition, in order to gain optimal market access, says business intelligence provider GBI Research.

According to the company’s latest CBR Pharma report*, this kind of analysis, known as Health Economics and Outcome Research (HEOR) is an important element of market access which encompasses aspects such as real-world data, quality of life, budget impact, and cost-effectiveness, along with clinical efficiency.

Rodrigo Gutierrez Gamboa, Managing Analyst for GBI Research, states that: “Traditionally, once a drug was registered in a country, it was automatically reimbursed and available for an eligible population of patients. Today, however, regulatory approval does not guarantee market access, as the cost-effectiveness of any given drug must be thoroughly demonstrated before it receives coverage in a health system.

Currently, a significant number of European payers, continuing to play a key role in pricing decisions, expect companies to conduct comparator trials for easy evaluation of drug effectiveness in order to list the drugs on formularies.

*Evolving Market Access Strategies – Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

This report provides analysis of the key elements of pharmaceutical market access, such as Health Economics and Outcome Research (HEOR) and Health Technology Assessment (HTA), as well as pricing and reimbursement strategies for pharmaceutical products. It includes information on market policies in the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, along with a number of relevant case studies.View Report

………………………………………………………………………………………………………………………………………………………………………..

Asia-Pacific Type 2 Diabetes Mellitus Treatment Market Will Exceed $10 Billion by 2021

The treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%, according to business intelligence provider GBI Research.

The company’s latest report* states that this substantial growth, which will occur across the countries of China, India, Japan and Australia, will be driven by the rapidly expanding prevalence population resulting from increasingly aging populations and sedentary lifestyles. Higher diagnosis and treatment rates, due to rising disease awareness among the public, will also play a role.

Aswini Nath, Senior Analyst for GBI Research, says: “T2DM is becoming an increasingly common problem in APAC regions as they become more industrialized and diets become more Westernized. In line with this, there is a very large and innovative pipeline, suggesting a strong potential for unmet needs to be addressed in coming years.

“The late-stage pipeline contains a high proportion of products from established drug classes, with improved dosing regimens and administration routes in comparison to currently marketed products. This suggests that unmet needs relating to patient convenience and ease of use will be addressed most significantly over the forecast period.”

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.View Report

………………………………………………………………………………………………………………………………………………………………………..

Alzheimer’s Disease Market Will More Than Double to $10.4 Billion by 2021

The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%, according to business intelligence provider GBI Research.

The company’s latest report* states that such impressive growth, which will occur across the eight major markets (8MM) of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, will be primarily driven by increased disease prevalence during the forecast period.

Yasser Mushtaq, Senior Analyst for GBI Research, says Alzheimer’s disease is significantly more common in the older population and incidence rates increase rapidly after the age of 65.

Mushtaq comments: “The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.

“Despite the urgent need to develop more effective treatments for Alzheimer’s disease, thorough research is being carried out into understanding the disease, as its underlying pathology remains unknown.

“However, these extensive studies have helped to develop the research and development process within this indication, providing hope for the future of Alzheimer’s disease therapeutics.”

*Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 – Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

This report provides analysis of the Alzheimer’s disease therapeutics space across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, with annualized market data from 2014 and forecast to 2021. It includes information on the current clinical and commercial landscape, and the composition of the Alzheimer’s disease market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.View Report

………………………………………………………………………………………………………………………………………………………………………..

China Pushed Global Renewable Installed Capacity Beyond 900 Gigawatts in 2015

China was the world’s leading market across a number of renewable energy technologies in 2015 and helped to drive global renewable installed capacity to an estimated 913.48 Gigawatts (GW), says research and consulting firm GlobalData.

The company’s latest report* states that China led the world for annual capacity additions in solar, biopower, small hydropower and onshore wind in 2015, although the National Development and Reform Commission confirmed reductions in the cut to China’s onshore wind feed-in tariffs, for projects approved after January 1, 2015 or commissioned after January 1, 2016.

Ankit Mathur, GlobalData’s Practice Head for Power, says that China consolidated its position as the leading installer of solar power capacity in 2015, as part of a bid to increase renewable technologies and drive down greenhouse gas emissions.

Mathur explains: “China became the largest consumer of solar photovoltaic (PV) modules in 2014, overtaking both Japan and the US. China’s annual solar PV installations have grown rapidly over the past few years, from 500 Megawatts in 2010, to 10.6 GW in 2014, and an estimated 18.43 GW in 2015.

“In 2014, Japan and the US stood second and third, with annual solar PV installations of about 10 GW and 6.2 GW, respectively. However, both countries added an estimated 8.2 GW each in 2015.”

GlobalData’s report also states that while the major markets of Europe and North America have historically had the best renewables track record, and will continue to expand renewable capacity, developing markets such as China have shown commitment to increasing their installed renewable capacity, driven by an increasing global emphasis on policies tackling climate change.

The most important recent development in global climate change policy in 2015 was the United Nations 21st Conference of the Parties (COP21) in Paris, which proposed a number of ambitious targets..View Full Report

………………………………………………………………………………………………………………………………………………………………………..

APAC Breast Cancer Market Would Reach $3.4 Billion by 2021

APAC Breast Cancer Market Would Reach $3.4 Billion by 2021, predicts GBI Research.

The Asia-Pacific (APAC) breast cancer market is poised to experience substantial expansion from $1.9 billion in 2014 to $3.4 billion by 2021, at a steady CAGR of 8.5%, as per the business intelligence provider GBI Research.

A latest report from the company, states that anticipated growth would be driven mainly by the change in lifestyle patterns, aging population, improvement in survival rates and rise in number of new drug approvals supplementing the present market leaders across the APAC regions of India, China, Japan and Australia.

Popular drugs, such as Afinitor and Herceptin, are expected to be used in conjunction with various promising breast cancer pipeline treatments including abemaciclib, LEE 011, buparlisib, Neuvax, and olaparib all of which are predicted to be approved by 2021 and have shown noteworthy clinical benefit in trials.

Such therapies are experiencing rise in adoption owing to their increased usage in conjunction with chemotherapy. Moreover, the strong efficacy profile of these targeted therapies has resulted in conducive reimbursement and rising uptake in Japan and Australia.

The report further analyses that………..Read more

……………………………………………………………………………………………………………………..

Russia and Kazakhstan Would Lead the Planned Upstream Projects in the Former Soviet Union to 2025

LONDON, UK, 1 March 2016 – Russia is accountable for 25 key crude and natural gas projects anticipated to initiate operations by 2025, leading the Former Soviet Union’s (FSU) oil and gas production, predicts research and consulting firm GlobalData.

According to a latest report from GlobalData, the couple of other key planned projects in the FSU geography are in Kazakhstan, headed by the colossal Kashagan crude oil project, which is considered to be the largest discovery, globally in the last 30 years.

Russia would account for majority of the planned oil and gas production across the FSU region, with Gazprom accounting for the highest oil and gas production in the geography by 2025.

“The company’s key planned assets are anticipated to account for 1.89 million barrels of oil equivalent per day (mmboed) of production, followed by key projects at Lukoil and Rosneft at 0.92 mmboed and 0.88 mmboed respectively.”

Rosneft would lead the FSU region in context to the operatorship of the planned projects, and would operate 10 planned assets, the maximum number in the region followed by Lukoil and Gazprom at second and third place respectively.

The report further analyses that…………Read more

……………………………………………………………………………………………………………………..

Global 3D Camera Market to Reach $19,419.0 Million by 2022

 Link to Media Release
New York, NY — (SBWIRE) — 03/03/2016 — The global 3D camera market is expected to reach a market size of $19,419.0 million by 2022, growing at a CAGR of nearly 50% during the forecast period, 2016-2022. Major 3D technologies available in the 3D camera market are Time of flight, stereo vision and structured light imaging. The simplicity and easy to access property of stereo vision technology had made it most popular among end customers compared to other two technology. Hence, the market for stereo vision 3D camera would dominate the market throughout the forecast period. The segment is expected to register market size of $10,655.5 million by 2022 growing at CAGR of 48.2% during 2016-2022. However, Time of flight camera technology would witness highest CAGR of 55.4% during the forecast period.Read More…

……………………………………………………………………………………………………………………..

Tempered Glass Market to reach $54 billion, globally, by 2022

PRFree.Org (Press Release) Mar 1, 2016

Link to Media Release

Sigma Market Research adds a new report titled “Tempered Glass Market Analysis By Application (Automotive, Construction) And Segment Forecasts To 2022”.

The report offers an insightful elaboration on the market with analysis on market dynamics, value chain, product application & services, and market shares, PESTEL and Porter’s five forces analysis. The report highlights the existing market trends and forecasts till 2022, driving and restraining factors, along with the exhaustive segmentation across product, service, and application segments….Read more

……………………………………………………………………………………………………………………..

Global Integrated Systems Market Expected to Reach USD 24.02 Billion by 2020

NewswireToday – /newswire/ – New York, NY, United States, 2016/02/29

Link to the Media Release

This report provide analysis of integrated systems market highlighting the key influencing factors, market trends, segmentation along with the forecasts – SigmaMarketResearch.com.

Sigma Market Research announces addition of a new report titled “Global Integrated Systems Market Analysis By Product (Integrated Platform/ Workload Systems, Integrated Infrastructure Systems), By Service (Integration & Installation, Consulting, Maintenance & Support), By Application (BFSI, IT & Telecom, Retail, Manufacturing, Healthcare) And Segment Forecasts To 2020”. The report provides an in-depth insights for the market with coverage on market dynamics, product application & services, value chain, and market shares and Porter’s five forces and PESTEL analysis. The report highlights the current market trends and forecasts, key influencing factors, along with exhaustive segmentation across product, service, and application categories...Read More

………………………………………………………………………………………………………………………………………………………………………..

Geosynthetic Clay Liner Market to Reach $488 million, globally, by 2022 – Sigma Market Research

 NEW YORKFeb. 28, 2016PRLog — Sigma Market Research announces addition of a new report titled “Geosynthetic Clay Liner Market Analysis By Application (Containment & Wastewater Treatment, Landfill, Roadways & Civil Construction) And Segment Forecasts To 2022”. The report provides an in-depth insights for the Geosynthetic Clay Liners market with coverage on application and regional outlook, market dynamics, value chain, and market shares and Porter’s five forces and PESTEL analysis.

The report highlights the market opportunities pertaining to the application in diverse sectors including containment & wastewater treatment, landfill and roadways & civil construction. The regional markets namely North America (U.S), Europe (Germany), Asia Pacific (China, Australia), Latin America (Brazil) and Middle East (Saudi Arabia)& Africa.
Read More..

……………………………………………………………………………………………………………………..

Managed Security Services (MSS): An Opportunistic IT Security Segment, Globally

Managed Security Services (MSS) can be understood as an arrangement for the remote management and monitoring of IT security through the 3rd party vendors thereby having an effective secured IT environment for the organizations.

With the increase in the incidents of security breaches and other malicious activities, the organizations worldwide are experiencing rapid growth in security concerns. Further, the rising costs for having a flawless IT security environment is posing a significant challenge to these organizations across sectors. With the increase in the IT talent pool, globally, there has been a significant rise in the number of professional hackers. As a negative side to this there has been a rapid increase in the organized cybercrime. Such a risk of data breaches has led to the significant cost increase in securing the IT environment worldwide. Such inflated IT budgets are continuously becoming a bottleneck for the companies across industries….Read more